Please login to the form below

Not currently logged in
Email:
Password:

Fampyra

This page shows the latest Fampyra news and features for those working in and with pharma, biotech and healthcare.

NICE denies two drugs in new MS guidance

NICE denies two drugs in new MS guidance

NICE denies two drugs in new MS guidance. Sativex and Fampyra too costly for NHS in England. ... Michelle Mitchell, chief executive of the MS Society, said: “ NICE's decision to reject Sativex and Fampyra as treatment options is really disappointing.

Latest news

  • FDA approves Biogen Idec's long-acting MS therapy FDA approves Biogen Idec's long-acting MS therapy

    Plegridy is Biogen Idec's fifth MS treatment to reach the market joining Avonex, Tysabri (natalizumab), fast-growing oral therapy Tecfidera (dimethyl fumarate) and Fampyra (fampridine).

  • IQWiG backs BMS' Yervoy for melanoma IQWiG backs BMS' Yervoy for melanoma

    delivered a negative appraisal for Biogen Idec's multiple sclerosis drug Fampyra (prolonged-release fampridine).

  • IQWiG turns down GSK’s lupus drug Benlysta IQWiG turns down GSK’s lupus drug Benlysta

    IQWiG turns down GSK’ s lupus drug Benlysta. German HTA body also declines to back Biogen Idec’ s Fampyra in its draft assessments. ... Further no from IGWiG for Biogen Idec's Fampyra. In addition to its Benlysta guidance, IQWiG also released a draft

  • Avonex slowdown hits Biogen Idec in first quarter Avonex slowdown hits Biogen Idec in first quarter

    Fampyra  (prolonged-release fampridine) for improving walking ability in MS patients made a solid start with $15m in revenues in the quarter following launches in Germany, the UK, Australia, Denmark, Norway,

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics